Introduction
Retroperitoneal fibrosis (RPF) is a rare disease associated with the development of fibrous tissue and/ or chronic inflammatory infiltrates in the retroperitoneal space that envelop the aorta, iliac vessels, and ureters [1] . In approximately two thirds of the patients, no apparent cause for the development of the disease is found (idiopathic RPF). In these cases autoimmune pathogenesis is suspected [1, 3] . In the remaining third of the cases, RPF is associated with the presence of malignancies within or outside the retroperitoneal space, hemorrhage, foreign bodies, surgical intervention, and/or radiotherapy in the retroperitoneum, systemic connective tissue disease, intake of certain medications (e.g., beta-blockers, methysergide, methyldopa, or ergotamine) [1] .
In up to 15% of the patients, additional fibrosis conditions outside the retroperitoneal space are observed [1] [2] [3] [4] [5] [6] [7] [8] [9] , probably as a manifestation of a systemic fibrosing condition, such as mesenterial, mediastinal, pulmonary or liver fibrosis; fibrosing periarthritis; pericarditis; pleuritis; fibrosing pseudotumor of the orbit; sclerosing cholangitis and sialadenitis; Riedel's thyroiditis; and pancreatic fibrosis. Pancreatic involvement is rare in RPF and usually presents as pseudotumor of fibrotic tissue enveloping the pancreas or as sclerosing pancreatitis [7] [8] [9] . The cases of sclerosing pancreatitis are considered an immunoglobulin (Ig) G4-related disease, and biopsy specimens of the retroperitoneal pseudotumor usually reveal marked lymphoplasmacytic infiltration (immunoreactive for anti-IgG4 antibodies) with dense fibrosis [10] . In addition, in patients with RPF with pancreatic involvement, high IgG4 serum levels have been described [10] . In both forms of pancreatic involvement, aggressive immunosuppressive treatment leads to a rapid reduction of fibrous tissue infiltrates [7] [8] [9] [10] .
Here, we present a 50-year-old female patient diagnosed with RPF in 2003 and, after a complete remission induced by corticosteroids and tamoxifen, developed a late recurrence with pancreatic involvement.
Case Report
A 50-year-old female patient presented at the Clinic of Nephrology in August 2003. The patient reported dull low back pain since 2001. In March 2003, she was admitted to a local hospital for stenosis of the right ureter with infected hydronephrosis on the right side. Ureteral reconstruction was performed, and a double-J (DJ) stent was implanted in the right ureter. In June 2003, the patient was readmitted for bilateral hydronephrosis. Abdominal echography scan, percutaneous and retrograde pyelography, and computed tomography (CT) revealed bilateral hydronephrosis and tumor-like formation in the left adnexes. The patient received a second operation, and extensive retroperitoneal fibrosis was found. The patient underwent liberation and peritonealization of both ureters, DJ stents were implanted, and a left-side adnexectomy was made.
The pathological examination of the retroperitoneal and left periadnexal infiltrates revealed fibrotic tissue. No tumor formation was found in the left adnexes, and the pelvic mass consisted of fibrotic tissue and inflammatory infiltrates. The patient was admitted to our clinic in August 2003 after antibacterial treatment for urinary tract infection. After causes for the development of RPF were not found (i.e., intake of medications, trauma, hemorrhage, radiotherapy, or tumors within the retroperitoneum), the diagnosis of primary RPF was accepted, and pathogenic treatment with corticosteroids (dehydrocortisone 0.5 mg/kg/day initial dose), tamoxifen, and agapirin was initiated. Complete remission was achieved (including reduction of the fibrous tissue as determined by CT and magnetic resonance imaging [MRI] ). For the period January 2005 to May 2007, the patient remained in stable remission. At the diagnosis of RPF, the patient had incipient renal failure (serum creatinine 130-160 mmol/l), and three months after the initiation of active treatment, renal function returned to normal and has remained normal until the writing of this report. At the first admission to our clinic antinuclear and anti-neutrophil cytoplasmic antibodies were negative, anticardiolipin antibodies, IgG, IgM, IgA, and C3 and C4 complement levels were within the normal limits.
In May 2007, the patient reported pain in both hypochondria, in the epigastrium, and in the spine and was readmitted to our clinic. Her physical status at the admission was normal except for palpatory pain in the epigastrium and in the left hypochondrial area and bilateral positive renal percussion.
Clinical laboratory investigations revealed an elevated erythrocyte sedimentation rate of 28 mm/I/ hour, leukocyturia, and bacteriuria. All hematological and biochemical parameters were within the normal limits. The patient had negative antinuclear and antineutrophil cytoplasmic antibodies and normal levels of IgG, IgM, IgA, anti-cardiolipin antibodies, and C3 and C4 complements.
Abdominal echography scan ( Figure 1A -D) revealed a hypoechogenic zone adjacent to (10-12 mm from) the pancreas and the large vessels, discrete dilation of the right renal pelvis, and several heterogenic zones adjacent to (15-18 mm from) the urinary bladder (lymph nodes). An abdominal echography scan 15 days later (Figure 2 ) revealed three hypoechogenic masses adjacent to the pancreas. The patient was referred for CT and MRI of the abdomen and the pelvis to examine for the recurrence of RPF and/or pancreatic tumor.
The CT and MRT of the abdomen and pelvis ( Figure 3 and 4) revealed a C-shaped mass in the retroperitoneal space surrounding the upper, posterior, and lower surfaces of the pancreas, celiac trunk, hepatic artery, and the initial segments of the lineal and the left gastric artery; no enlarged lymph nodes; and persistent bilateral hydronephrosis; in summary, recurrence of retroperitoneal fibrosis with pancreatic involvement.
Echocardiographic examination revealed increased echogenicity of the pericardium at the posterior wall of the left ventricle, normal heart valves, normal left ventricle kinetics, systolic and diastolic function.
Considering the results of the imaging studies, the diagnosis of RPF recurrence with pancreatic, vascular and probable pericardial involvement was accepted. After antibacterial treatment of urinary tract infection, pathogenic treatment with dehydrocortisone 40 mg/day and azathioprine 100 mg a day was initiated.
Abdominal echography one month after the initiation of immunosuppressive treatment revealed no visible pelvic/abdominal lymph nodes, a decrease in peripancreatic masses by 10 mm, and mild dilation of the right renal pelvis.
Discussion
RPF is a rare disease associated with the development of chronic inflammation and fibrogenesis in the retroperitoneal space. In some cases, other fibrosing processes outside the retroperitoneum are observed, probably as a manifestation of a systemic fibroinflammatory condition. Pancreatic involvement in the RPF, manifested as pseudotumor or sclerosing pancreatitis, is very rare [1] [2] [3] [7] [8] [9] . Even fewer cases have pericardial involvement [1] [2] [3] .
The classical pathological features of RPF consist of the development of whitish-grey fibrous masses adjacent to the aortic bifurcation and iliac arteries. The fibrous tissue usually originates from the space between the last lumbar and the first sacral vertebra, surrounds the ureters and aorta, and rarely affects the posterior retroperitoneum [1] . Rarely, the fibrosing process may reach the duodenum and other intraperitoneal structures. Three histological stages of RPF have been described [11] : The clinical manifestations of RPF are nonspecific. Approximately 80% of patients report dull pain in the flank, back, lower abdomen, or scrotum; fatigue; malaise; loss of appetite; weight loss; and low-grade fever [1] . Occasionally, deep vein thrombosis or an abdominal mass, hydrocele, or lower limb edema may be present. In the case of intraperitoneal involvement, bowel obstruction may develop. In severe cases, aortic aneurysms, thromboses of the inferior vena caval, edema of the lower limbs, urosepsis, and endstage renal disease may develop. Laboratory changes in RPF are also nonspecific and can include elevated erythrocyte sedimentation rate and C-reactive protein levels, elevated creatinine and urea levels, normocytic normochromic anemia, hematuria, bacteriuria, and, rarely, polyclonal hypergammaglobulinemia or high alkaline phosphatase levels. In some cases, positive autoantibodies and low complement levels have been described, and in the cases of pancreatic involvement, high IgG4 serum levels have been described [10] .
The diagnosis of RPF is difficult because of the lack of typical clinical signs and symptoms. Usually, the diagnosis is based on the results of the imaging studies and histological verification. Abdominal echography is a tentative diagnostic method and yet, in RPF, it allows noninvasive dynamic follow-up and assessment of response to therapy, especially in patients with underlying renal failure. Conventional abdominal echography reveals the presence of unilateral or bilateral (but nonsymmetrical) hydronephrosis with or without renal/ureteral stones and renal parenchymal changes with or without changes in renal/parenchymal size [1, 12] . In the presence of urinary tract infection, abdominal echography may reveal acute focal or diffuse pyelonephritis or renal abscess [13] . The B-scan may reveal anisoechogenic or indistinct tumor-like masses in the retroperitoneal space. In the advanced stages of RPF, when "mature" fibrosis has developed, only unilateral or bilateral hydronephrosis is observed because the echogenicity of the fibrous tissue is similar to that of the adjacent structures. Doppler echography facilitates the differentiation of RPF from retroperitoneal tumors (lack of neovascularization). Pulse Doppler echography allows differentiation of acute and chronic urinary tract obstruction. CT and MRI, especially with contrast enhancement, reveal the type and the extent/ spreading of fibrosis, allow dynamic follow-up and differentiation between RPF and malignancies in the retroperitoneal space.
The treatment of RPF consists of three main strategies: (1) antifibrotic/immunosuppressive agents for 6 to 24 months, including corticosteroids, cytotoxic medications such as azathioprine, colchicine, and agapurin); (2) surgical ureteral desobstruction, including implantation of DJ ureteral stents, open ureterolysis, or laparoscopic ureteral liberation with or without peritonealization; and (3) prevention/treatment of urinary tract infections and chronic renal failure. Approximately half of the patients experience a recurrence of RPF within 2 to 5 years after complete remission is achieved.
Our patient represents an interesting clinical case in the following aspects: (1) The disease manifested with the "classical" clinical signs and symptoms of RPF, namely, flank and low-back pain, bilateral hydronephrosis, tumor-like masses in the pelvis, persistent urinary tract infections, and incipient renal failure; (2) although the diagnosis is based on the results of the imaging studies and the histological verification, the biopsy specimens were not investigated for IgG4; (3) complete remission with disappearance of fibrosis was achieved in a relatively short time; and (4) approximately two years after complete remission was achieved, the patient developed recurrence of fibrosis with pancreatic, intraperitoneal, and probable pericardial involvement, and no other fibrosing condition outside the abdomen was observed (i.e., sclerosing cholangitis, sclerosing sialadenitis, orbital pseudotumor, or Riedel's thyroiditis).
In conclusion, we report a case of recurrent RPF with pancreatic involvement. This case highlights the crucial role of the imaging and histological methods in the diagnosis of RPF and the importance of the "team approach" in the diagnosis and treatment of this rare disease.
